Narrative review of migraine management in patients with renal or hepatic disease
- 28 January 2023
- journal article
- review article
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 63 (1), 9-24
- https://doi.org/10.1111/head.14437
Abstract
Objectives/BackgroundTreatment of migraine in the setting of either renal or hepatic disease can be daunting for clinicians. Not only does the method of metabolism have to be considered, but also the method of elimination/excretion of the parent drug and any active or toxic metabolites. Furthermore, it is difficult to think about liver or kidney disease in isolation, as liver disease can sometimes contribute to impaired renal function and renal disease can sometimes impair hepatic metabolism, through the cytochrome P450 system. MethodsA detailed search for terms related to liver disease, renal disease, and migraine management was performed in PubMed, Ovid Medline, Embase, and the Cochrane Library.For each medication, product labels were retrieved and reviewed using the US FDA website, with additional review of IBM Micromedex, LiverTox, and the Renal Drug Handbook. ResultsThis manuscript provides an overview of migraine drug metabolism and how it can be affected by liver and renal impairment. It reviews the standard terminology recommended by the US Food and Drug Administration for the different stages of hepatic and renal failure. The available evidence regarding the use of abortive and preventative medicines in the setting of organ failure is discussed in detail, including more recent therapies such as lasmiditan, gepants, and calcitonin gene-related peptide antibodies. ConclusionsFor acute therapy, the use of NSAIDS should be limited, as these carry risk for both severe hepatic and renal disease. Triptans can be selectively used, often with dose guideline adjustments. Ubrogepant may be used in severe hepatic disease with dose adjustment and lasmiditan can be used in end stage renal disease. Though non-medicine strategies may be the most reasonable initial approach, many preventative medications can be used in the setting of hepatic and renal disease, often with dose adjustment. This review provides tables of guidelines, including reduced dosing recommendations, for the use of abortive and preventative migraine medications in hepatic and renal failure.Keywords
This publication has 67 references indexed in Scilit:
- Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic reviewFamily Practice, 2013
- Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adultsNeurology, 2012
- New-onset headache in an elderly man with uremia that improved only after correction of hyperphosphatemia ("uremic headache"): a case reportJournal of Medical Case Reports, 2011
- Pain Management in the Cirrhotic Patient: The Clinical ChallengeMayo Clinic Proceedings, 2010
- Caffeine-withdrawal headache induced by hemodialysisThe Journal of Headache and Pain, 2009
- Hemodialysis headacheClinical Nephrology, 2009
- Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone)Pain Practice, 2008
- Use of Over-the-Counter Analgesics in Patients with Chronic Liver DiseaseDrug Safety, 2008
- Analgesics and the kidney: Summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc Committe of the National Kidney FoundationAmerican Journal of Kidney Diseases, 1996
- Acute Hepatic Failure Associated with the Use of Sodium ValproateThe New England Journal of Medicine, 1979